Imaging Pituitary ActiVation by Exendin

NCT03923114 · Completed

Last updated 2026-05-28

This clinical trial is testing a new imaging method using a radioactive tracer to see how it is taken up by the pituitary gland in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) study

Participants 20 people

Who can join Ages 18+ · all sexes

Timeline Started 2019-05 · est. completion 2024-04

Where 1 site · Netherlands

What this study is testing ClinicalTrials.gov NCT03923114 ↗

Description as written by the study sponsor.

The main goal is the comparison of pituitary uptake of Ga-68-NODAGA-exendin-4 in patients with and without adequate response (based on HbA1c or weight loss) to GLP-1R agonist treatment.

Treatments tested

Ga-68-NODAGA-exendin-4 PET/CT Radiation

PET/CT imaging after injection with Ga-68-NODAGA-exendin-4

Main thing measured	Pituitary uptake of Ga-68-NODAGA-exendin
Sponsor	Radboud University Medical Center
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03923114 ↗